FDB to triple UK microbial production capacity as Fujifilm commits to $83 million investment
Fujifilm Diosynth Biotechnologies will triple microbial production capacity at its UK Teesside facility after joint owner Fujifilm Corporation pledged to invest 9 billion yen (USD83 million) in the biologics focused CDMO.
The expansion – scheduled to be operational by 2022 -- will include a new production line with 2 X 2000L fermenters and a modular purification suite and an upgrade to utilities to make them ready for high volume production.
"Fujifilm has committed to supporting the biopharmaceutical industry and invested aggressively in both capital and technology for producing such as antibodies and gene therapies,” said Takatoshi Ishikawa, executive vice president and general manager of the Bio CDMO Division of Fujifilm.
He added that the expansion was a response to current increased demand for microbial production.
“From our pAVEway expression technology to our commercial capabilities, we are well suited to support customers at all stages of the product development process,” said Paul Found, chief operating officer, FDB, United Kingdom.
Fujifilm said it is targeting sales of 100 billion yen in the Bio CDMO business – which offers both biopharmaceuticals and small molecule pharmaceuticals -- in FY2021.
FDB is a joint venture between Fujifilm and Mitsubishi Corporation and also has sites in Texas and North Carolina in the US and Hillerød, Denmark.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...